Responses and outcomes. (A) Response according to the primary end point in the intention-to-treat population; patients who discontinued study treatment before evaluation for response at the end of cycle 30 (n = 11) were classified as not evaluable (NE). (B) Forest plot of primary end point based on baseline characteristics. Primary end point was the rate of patients achieving uMRD by flow cytometry in BM and PB with CR/CRi at cycle 31. (C) TLS risk alluvial plot. H1, alternative hypothesis; mMRD, measurable minimal residual disease; NA, not available.